AR114392A1 - Tratamiento de pacientes con enfermedad de fabry clásica - Google Patents
Tratamiento de pacientes con enfermedad de fabry clásicaInfo
- Publication number
- AR114392A1 AR114392A1 ARP190100287A ARP190100287A AR114392A1 AR 114392 A1 AR114392 A1 AR 114392A1 AR P190100287 A ARP190100287 A AR P190100287A AR P190100287 A ARP190100287 A AR P190100287A AR 114392 A1 AR114392 A1 AR 114392A1
- Authority
- AR
- Argentina
- Prior art keywords
- patient
- renal
- fabry disease
- reduce
- patients
- Prior art date
Links
- 208000024720 Fabry Disease Diseases 0.000 title abstract 3
- 239000012458 free base Substances 0.000 abstract 2
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 abstract 2
- 229950007469 migalastat Drugs 0.000 abstract 2
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000003907 kidney function Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862626992P | 2018-02-06 | 2018-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114392A1 true AR114392A1 (es) | 2020-09-02 |
Family
ID=65494622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100287A AR114392A1 (es) | 2018-02-06 | 2019-02-06 | Tratamiento de pacientes con enfermedad de fabry clásica |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210038579A1 (https=) |
| EP (2) | EP4316589A3 (https=) |
| JP (2) | JP2021512896A (https=) |
| KR (1) | KR20200128675A (https=) |
| CN (1) | CN112203657A (https=) |
| AR (1) | AR114392A1 (https=) |
| AU (2) | AU2019217603A1 (https=) |
| DK (1) | DK3749308T3 (https=) |
| ES (1) | ES2969263T3 (https=) |
| FI (1) | FI3749308T3 (https=) |
| HR (1) | HRP20240025T1 (https=) |
| HU (1) | HUE064761T2 (https=) |
| LT (1) | LT3749308T (https=) |
| PL (1) | PL3749308T3 (https=) |
| PT (1) | PT3749308T (https=) |
| RS (1) | RS65103B1 (https=) |
| SI (1) | SI3749308T1 (https=) |
| SM (1) | SMT202400027T1 (https=) |
| TW (2) | TWI869336B (https=) |
| WO (1) | WO2019157056A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2573498T3 (es) | 2006-05-16 | 2016-06-08 | Amicus Therapeutics, Inc. | Opciones de tratamiento para la enfermedad de Fabry |
| SI3470077T1 (sl) | 2008-02-12 | 2020-12-31 | Amicus Therapeutics, Inc. | Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
| CA3224537C (en) | 2017-05-30 | 2025-09-09 | Amicus Therapeutics, Inc. | USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE |
| CA3090496C (en) | 2018-02-06 | 2024-03-26 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| EP4282472A3 (en) | 2018-08-20 | 2024-02-21 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having a mutation in the gla gene |
| EP3851105B1 (en) | 2019-08-07 | 2026-03-04 | Amicus Therapeutics, Inc. | Migalastat for use in treating fabry disease in patients having a mutation in the gla gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| ES2573498T3 (es) * | 2006-05-16 | 2016-06-08 | Amicus Therapeutics, Inc. | Opciones de tratamiento para la enfermedad de Fabry |
| AU2008232614A1 (en) | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of Fabry disease using pharmacological chaperones |
| SI3470077T1 (sl) | 2008-02-12 | 2020-12-31 | Amicus Therapeutics, Inc. | Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
| KR102004114B1 (ko) * | 2016-03-22 | 2019-07-26 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| AR109103A1 (es) | 2016-07-19 | 2018-10-31 | Amicus Therapeutics Inc | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert |
| WO2019017938A1 (en) * | 2017-07-19 | 2019-01-24 | Amicus Therapeutics, Inc. | TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES |
-
2019
- 2019-02-06 SM SM20240027T patent/SMT202400027T1/it unknown
- 2019-02-06 RS RS20240081A patent/RS65103B1/sr unknown
- 2019-02-06 EP EP23200414.3A patent/EP4316589A3/en active Pending
- 2019-02-06 LT LTEPPCT/US2019/016853T patent/LT3749308T/lt unknown
- 2019-02-06 HU HUE19706182A patent/HUE064761T2/hu unknown
- 2019-02-06 KR KR1020207025688A patent/KR20200128675A/ko not_active Ceased
- 2019-02-06 JP JP2020542569A patent/JP2021512896A/ja not_active Withdrawn
- 2019-02-06 PL PL19706182.3T patent/PL3749308T3/pl unknown
- 2019-02-06 CN CN201980024335.8A patent/CN112203657A/zh active Pending
- 2019-02-06 EP EP19706182.3A patent/EP3749308B1/en active Active
- 2019-02-06 PT PT197061823T patent/PT3749308T/pt unknown
- 2019-02-06 DK DK19706182.3T patent/DK3749308T3/da active
- 2019-02-06 AR ARP190100287A patent/AR114392A1/es unknown
- 2019-02-06 AU AU2019217603A patent/AU2019217603A1/en not_active Abandoned
- 2019-02-06 FI FIEP19706182.3T patent/FI3749308T3/fi active
- 2019-02-06 SI SI201930691T patent/SI3749308T1/sl unknown
- 2019-02-06 ES ES19706182T patent/ES2969263T3/es active Active
- 2019-02-06 WO PCT/US2019/016853 patent/WO2019157056A1/en not_active Ceased
- 2019-02-06 HR HRP20240025TT patent/HRP20240025T1/hr unknown
- 2019-02-06 US US16/967,824 patent/US20210038579A1/en active Pending
- 2019-02-11 TW TW108104436A patent/TWI869336B/zh active
- 2019-02-11 TW TW113148020A patent/TW202537622A/zh unknown
-
2023
- 2023-11-13 JP JP2023192942A patent/JP2024026080A/ja active Pending
-
2025
- 2025-01-07 AU AU2025200074A patent/AU2025200074A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SMT202400027T1 (it) | 2024-03-13 |
| JP2021512896A (ja) | 2021-05-20 |
| HUE064761T2 (hu) | 2024-04-28 |
| CN112203657A (zh) | 2021-01-08 |
| ES2969263T3 (es) | 2024-05-17 |
| WO2019157056A8 (en) | 2020-12-03 |
| DK3749308T3 (da) | 2024-01-22 |
| RS65103B1 (sr) | 2024-02-29 |
| EP4316589A3 (en) | 2024-04-24 |
| SI3749308T1 (sl) | 2024-03-29 |
| WO2019157056A1 (en) | 2019-08-15 |
| AU2019217603A1 (en) | 2020-09-24 |
| EP3749308A1 (en) | 2020-12-16 |
| JP2024026080A (ja) | 2024-02-28 |
| CA3090499A1 (en) | 2019-08-15 |
| KR20200128675A (ko) | 2020-11-16 |
| HRP20240025T1 (hr) | 2024-03-29 |
| FI3749308T3 (fi) | 2024-01-18 |
| US20210038579A1 (en) | 2021-02-11 |
| TWI869336B (zh) | 2025-01-11 |
| EP3749308B1 (en) | 2023-10-25 |
| LT3749308T (lt) | 2024-02-12 |
| EP4316589A2 (en) | 2024-02-07 |
| PT3749308T (pt) | 2024-01-25 |
| TW201944998A (zh) | 2019-12-01 |
| AU2025200074A1 (en) | 2025-01-30 |
| PL3749308T3 (pl) | 2024-03-25 |
| TW202537622A (zh) | 2025-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| MX2022004137A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| CL2021003280A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| EA202090564A1 (ru) | Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| AR120399A1 (es) | Un método de tratamiento de un cáncer positivo para dll3 | |
| EA202190569A1 (ru) | Способы лечения болезни фабри у пациентов, имеющих мутацию в гене gla | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| MX2024004514A (es) | Terapia de combinacion con el inhibidor de o-glcnacasa (oga). | |
| ATE487480T1 (de) | Perhexilin zur behandlung von chronischer herzinsuffizienz | |
| AR117861A1 (es) | Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry | |
| EP4324522A3 (en) | Methods of treating fabry patients having renal impairment | |
| AR111971A1 (es) | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| AR109102A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| EA201992869A1 (ru) | Способы лечения пациентов с болезнью фабри, у которых имеется почечная недостаточность | |
| BR112013017829A2 (pt) | método de tratamento de um paciente com sintomas de prostatite e/ou síndrome da dor pélvica e método de tratamento de um paciente com sintomas de prostatite crônicas/síndrome de dor pélvica crônica |